Resveratrol and Longevity: What the Evidence Actually Says About the Anti-Aging Molecule

The Sinclair Program and Sirtris

David Sinclair’s Harvard laboratory drove much of the subsequent research and commercialization. Sinclair and colleagues co-founded Sirtris Pharmaceuticals, which developed proprietary SRT compounds intended to be more potent SIRT1 activators than resveratrol itself. GlaxoSmithKline acquired Sirtris in 2008 for $720 million. Development of the lead compound SRT501, a formulated resveratrol, was halted in 2010, and GSK closed Sirtris in 2013, folding its remaining SRT compounds into its own research.

The Assay Artifact Problem

The mechanism came under direct challenge. Pacholec and colleagues at Pfizer (Journal of Biological Chemistry, 2010) reported that resveratrol and the SRT compounds only activated SIRT1 when the deacetylation assay used a fluorophore-tagged peptide substrate. When the fluorophore was removed and native substrates were used, activation disappeared. This suggested the effect was an assay artifact rather than direct enzyme activation. Sinclair’s group responded with follow-up work proposing allosteric activation that depends on hydrophobic motifs in certain native substrates (Hubbard et al., 2013). The dispute has not been fully resolved. What is clear is that “resveratrol directly activates SIRT1” is no longer a settled statement.

The commercial arc of Sirtris is instructive. GSK paid $720 million in 2008 and had closed the unit by 2013. If direct sirtuin activation had been robust and reproducible, a pharmaceutical company with those resources would have found a clinical indication. The absence of an approved sirtuin-activator drug two decades after the founding paper is itself evidence.

The Mouse Data

The mouse literature is the most-cited part of the resveratrol lifespan case. The critical qualification: extension was most reliably observed in mice on obesogenic diets, where resveratrol appeared to protect against metabolic dysfunction rather than extend intrinsic lifespan. Miller and colleagues (Journals of Gerontology, 2011) at the NIA Interventions Testing Program tested resveratrol at multiple doses across three sites and found no lifespan extension in genetically heterogeneous mice on standard chow. This is the field’s most rigorous negative result.

The Primate Study

A 2013 study in rhesus monkeys on a high-fat, high-sugar diet (Jimenez-Gomez et al., Cell Metabolism) gave resveratrol for two years and found improved insulin sensitivity and less inflammation in visceral (but not subcutaneous) fat; it did not measure lifespan. A lifelong study in 33 male grey mouse lemurs (Pifferi et al., Communications Biology, 2025) found better cognitive and motor performance at middle age and a longer median lifespan in the resveratrol group (7.9 vs 6.4 years), but no significant effect on all-cause or age-related mortality, and faster grey-matter atrophy in old age. No primate resveratrol study has demonstrated a significant survival benefit.

Summary of the Preclinical Case

Verdict: Species and diet dependent, not general.

Yeast: inconsistent, and mechanism disputed. Worms and flies: inconsistent. Mice: benefits concentrated in obesogenic-diet models, absent under rigorous NIA-ITP protocols. Primates: no significant survival benefit. The lifespan claim generalized poorly as researchers moved up the phylogenetic tree.

What This Means for Doses in Trials

Many cell-culture effects of resveratrol require micromolar concentrations (chemopreventive effects need at least about 5 μM), so to reach them with free resveratrol, oral doses would need to be enormous, or delivery would need to be reformulated. Micronized formulations (SRT501), phospholipid complexes, and nanoformulations have all been tested to improve bioavailability. Micronized SRT501 at 5 g/day gave mean plasma levels about 3.6-fold higher than published values for standard resveratrol at the same dose (Howells et al., 2011), but still only at gram-level doses. Even a single 5 g oral dose produced a mean peak plasma resveratrol level of only about 2.4 μM in healthy volunteers (Boocock et al., 2007), and repeated doses of 2.5 g/day or more cause gastrointestinal side effects (Brown et al., 2010).

The Metabolite Question

An open question is whether resveratrol glucuronides and sulfates themselves have biological activity, or whether they can be deconjugated back to free resveratrol in target tissues. Cell and mouse work suggests sulfate conjugates can be converted back to free resveratrol inside some cells (Patel et al., 2013). This remains an active area of research and a hedge against the bioavailability critique, but it does not rescue the case for oral resveratrol as a systemic longevity intervention.

The Dose Disparity

An average 150 mL glass of red wine contains roughly 0.3 mg of trans-resveratrol (Stervbo et al., 2007); even a glass of Pinot Noir, among the richest varieties, averages only about 0.5 mg. Human trials showing metabolic effects generally use 150-1,000 mg/day. To reach a 150 mg trial dose from an average red wine alone would require around 500 glasses per day, an amount of alcohol that would be lethal many times over. The “resveratrol from red wine” health story is dose-incoherent by roughly three orders of magnitude.

This dose disparity is not disputed in the scientific literature. It is a well-known artifact of how the French paradox narrative developed before quantitative pharmacology entered the conversation. Whatever health effects moderate red wine consumption may or may not have, they cannot be attributed to resveratrol at the concentrations present. Other polyphenols (procyanidins, anthocyanins), ethanol itself at low doses, and confounding lifestyle factors are all candidates that explain the observational associations more coherently.

Insulin Sensitivity and Metabolic Health

The Timmers trial is the most-cited positive human study and is frequently invoked as evidence for “caloric restriction mimicry.” Its sample size (n=11) is small, and subsequent trials have not consistently replicated the metabolic profile. Poulsen and colleagues (Diabetes, 2013) randomized 24 obese but otherwise healthy men to high-dose resveratrol or placebo for 4 weeks and found no improvement in insulin sensitivity by hyperinsulinemic-euglycemic clamp, the reference measure, and no effect on blood pressure, body fat, or inflammatory markers. Yoshino and colleagues (Cell Metabolism, 2012) in nonobese postmenopausal women with normal glucose tolerance also found no effect on insulin sensitivity after 12 weeks at 75 mg/day.

Cardiovascular Markers

Meta-analyses of resveratrol trials for cardiovascular endpoints have been largely null. Sahebkar (Nutrition Reviews, 2013) pooled 7 RCTs (282 subjects) and found no significant effect on total, LDL, or HDL cholesterol or triglycerides. Fogacci and colleagues (Critical Reviews in Food Science and Nutrition, 2019) pooled 17 trials and found no significant overall effect on systolic or diastolic blood pressure; significant reductions appeared only in subgroups of trials using ≥300 mg/day and in people with diabetes. Endothelial function results (flow-mediated dilation) vary between trials, though a 2022 meta-analysis of 17 trials reported a small pooled improvement (Mohammadipoor et al., 2022).

Cognitive Endpoints

A 2014 trial by Witte and colleagues (Journal of Neuroscience, n=46 healthy overweight adults aged 50-75) reported better word retention and greater hippocampal functional connectivity after 26 weeks of 200 mg/day resveratrol compared with placebo. Turner and colleagues (Neurology, 2015) ran a 52-week phase 2 trial in 119 people with mild-to-moderate Alzheimer’s disease, escalating to 1,000 mg twice daily; CSF and plasma Aβ40 declined less than with placebo, but brain volume loss was greater in the resveratrol group, and the trial was not designed to show clinical benefit. Signals are preliminary; clinical significance is not established.

Verdict on Human Evidence

Modest, inconsistent, endpoint-dependent.

The most defensible human claims are possible blood pressure reductions at higher doses (seen only in subgroup analyses) and possible metabolic effects in obese or metabolically impaired populations. Nothing in the human trial literature approaches the “extends lifespan” or “mimics caloric restriction” framing used in popular writing.

Interactions to Consider

In 42 healthy volunteers taking 1 g/day for four weeks, resveratrol inhibited CYP3A4, CYP2D6, and CYP2C9 activity and induced CYP1A2, changes the authors warned could alter the effects of drugs cleared by those enzymes (Chow et al., 2010). Antiplatelet effects have been shown mainly in laboratory and animal studies; because of them, combining high-dose resveratrol with anticoagulants or antiplatelet drugs such as warfarin, aspirin, or NSAIDs is advised against as a precaution (Linus Pauling Institute), although clinical bleeding interactions have not been established. In cell studies, resveratrol bound the estrogen receptor and acted as an estrogen agonist at micromolar concentrations (Gehm et al., 1997), so people with a history of estrogen-sensitive cancers, or on tamoxifen or other hormone therapies, should discuss it with an oncologist. Its safety in pregnancy and lactation has not been established, so supplements are best avoided then (Linus Pauling Institute).

Product Quality Issues

Product analyses have found resveratrol content that departs from the label in both directions: in an Italian test of 14 brands, only five were within GMP range and two had none detectable (Rossi et al., 2012), while 19 of 20 Slovenian products differed from their declared content, more than half on the high side (Bensa et al., 2023). Because most commercial resveratrol is derived from Japanese knotweed rather than grape, emodin, an anthraquinone found in the plant (Avula et al., 2007) with laxative activity and liver toxicity at high or prolonged doses (Wang et al., 2024), can carry over into less purified extracts. Purified extracts specifying >98% trans-resveratrol and third-party testing are preferable.

NMN and NAD+ Precursors Have Largely Displaced Resveratrol

The center of gravity in longevity supplement discussions has moved to NAD+ precursors: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). The mechanistic story here is that sirtuin activity depends on cellular NAD+ availability, and NAD+ appears to decline with age in some tissues. Raising NAD+ through precursor supplementation is proposed as a more direct intervention than trying to activate sirtuins pharmacologically. NR and NMN both raise blood NAD+ levels in human trials (Christen et al., 2026). Whether this translates to meaningful healthspan or lifespan effects is not yet established, but the mechanistic evidence is cleaner and the pharmacokinetics are far more favorable than resveratrol’s.

Resveratrol is still sometimes co-formulated with NMN in commercial products on the theory that it might potentiate sirtuin activity once NAD+ is raised. This is speculative. No trial has demonstrated additive or synergistic benefit of the combination against NMN alone in humans.

Where Resveratrol Still Has a Reasonable Case

The most defensible modern use cases for resveratrol are as an adjunct in metabolic syndrome or insulin resistance where modest effects have been reported, and as a research compound. It is not a longevity drug in any evidence-based sense. Consumers who want polyphenol intake from food are better served by eating berries, grapes, dark chocolate, and other polyphenol-rich foods where the compounds arrive alongside their natural cofactors.